The Market Reports

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Mammalian Biopharmaceutical Service Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Cell Line Development
1.2.3 Analytical Testing
1.2.4 Technology Transfer
1.2.5 Formulation Development
1.2.6 Others
1.3 Market by Application
1.3.1 Global Mammalian Biopharmaceutical Service Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Pharmaceutical
1.3.3 Contract Research Organizations (CROs)
1.3.4 Academic and Research Institutes
1.3.5 Biotechnology Companies
1.3.6 Government Agencies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Mammalian Biopharmaceutical Service Market Perspective (2018-2029)
2.2 Mammalian Biopharmaceutical Service Growth Trends by Region
2.2.1 Global Mammalian Biopharmaceutical Service Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Mammalian Biopharmaceutical Service Historic Market Size by Region (2018-2023)
2.2.3 Mammalian Biopharmaceutical Service Forecasted Market Size by Region (2024-2029)
2.3 Mammalian Biopharmaceutical Service Market Dynamics
2.3.1 Mammalian Biopharmaceutical Service Industry Trends
2.3.2 Mammalian Biopharmaceutical Service Market Drivers
2.3.3 Mammalian Biopharmaceutical Service Market Challenges
2.3.4 Mammalian Biopharmaceutical Service Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Mammalian Biopharmaceutical Service Players by Revenue
3.1.1 Global Top Mammalian Biopharmaceutical Service Players by Revenue (2018-2023)
3.1.2 Global Mammalian Biopharmaceutical Service Revenue Market Share by Players (2018-2023)
3.2 Global Mammalian Biopharmaceutical Service Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Mammalian Biopharmaceutical Service Revenue
3.4 Global Mammalian Biopharmaceutical Service Market Concentration Ratio
3.4.1 Global Mammalian Biopharmaceutical Service Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Mammalian Biopharmaceutical Service Revenue in 2022
3.5 Mammalian Biopharmaceutical Service Key Players Head office and Area Served
3.6 Key Players Mammalian Biopharmaceutical Service Product Solution and Service
3.7 Date of Enter into Mammalian Biopharmaceutical Service Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Mammalian Biopharmaceutical Service Breakdown Data by Type
4.1 Global Mammalian Biopharmaceutical Service Historic Market Size by Type (2018-2023)
4.2 Global Mammalian Biopharmaceutical Service Forecasted Market Size by Type (2024-2029)
5 Mammalian Biopharmaceutical Service Breakdown Data by Application
5.1 Global Mammalian Biopharmaceutical Service Historic Market Size by Application (2018-2023)
5.2 Global Mammalian Biopharmaceutical Service Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Mammalian Biopharmaceutical Service Market Size (2018-2029)
6.2 North America Mammalian Biopharmaceutical Service Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Mammalian Biopharmaceutical Service Market Size by Country (2018-2023)
6.4 North America Mammalian Biopharmaceutical Service Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Mammalian Biopharmaceutical Service Market Size (2018-2029)
7.2 Europe Mammalian Biopharmaceutical Service Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Mammalian Biopharmaceutical Service Market Size by Country (2018-2023)
7.4 Europe Mammalian Biopharmaceutical Service Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Mammalian Biopharmaceutical Service Market Size (2018-2029)
8.2 Asia-Pacific Mammalian Biopharmaceutical Service Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Mammalian Biopharmaceutical Service Market Size by Region (2018-2023)
8.4 Asia-Pacific Mammalian Biopharmaceutical Service Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Mammalian Biopharmaceutical Service Market Size (2018-2029)
9.2 Latin America Mammalian Biopharmaceutical Service Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Mammalian Biopharmaceutical Service Market Size by Country (2018-2023)
9.4 Latin America Mammalian Biopharmaceutical Service Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Mammalian Biopharmaceutical Service Market Size (2018-2029)
10.2 Middle East & Africa Mammalian Biopharmaceutical Service Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Mammalian Biopharmaceutical Service Market Size by Country (2018-2023)
10.4 Middle East & Africa Mammalian Biopharmaceutical Service Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lonza
11.1.1 Lonza Company Detail
11.1.2 Lonza Business Overview
11.1.3 Lonza Mammalian Biopharmaceutical Service Introduction
11.1.4 Lonza Revenue in Mammalian Biopharmaceutical Service Business (2018-2023)
11.1.5 Lonza Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Mammalian Biopharmaceutical Service Introduction
11.2.4 Novartis Revenue in Mammalian Biopharmaceutical Service Business (2018-2023)
11.2.5 Novartis Recent Development
11.3 KBI Biopharma
11.3.1 KBI Biopharma Company Detail
11.3.2 KBI Biopharma Business Overview
11.3.3 KBI Biopharma Mammalian Biopharmaceutical Service Introduction
11.3.4 KBI Biopharma Revenue in Mammalian Biopharmaceutical Service Business (2018-2023)
11.3.5 KBI Biopharma Recent Development
11.4 3P Biopharmaceuticals
11.4.1 3P Biopharmaceuticals Company Detail
11.4.2 3P Biopharmaceuticals Business Overview
11.4.3 3P Biopharmaceuticals Mammalian Biopharmaceutical Service Introduction
11.4.4 3P Biopharmaceuticals Revenue in Mammalian Biopharmaceutical Service Business (2018-2023)
11.4.5 3P Biopharmaceuticals Recent Development
11.5 Sartorius Stedim Biotech
11.5.1 Sartorius Stedim Biotech Company Detail
11.5.2 Sartorius Stedim Biotech Business Overview
11.5.3 Sartorius Stedim Biotech Mammalian Biopharmaceutical Service Introduction
11.5.4 Sartorius Stedim Biotech Revenue in Mammalian Biopharmaceutical Service Business (2018-2023)
11.5.5 Sartorius Stedim Biotech Recent Development
11.6 Merck Millipore
11.6.1 Merck Millipore Company Detail
11.6.2 Merck Millipore Business Overview
11.6.3 Merck Millipore Mammalian Biopharmaceutical Service Introduction
11.6.4 Merck Millipore Revenue in Mammalian Biopharmaceutical Service Business (2018-2023)
11.6.5 Merck Millipore Recent Development
11.7 AGC Biologics
11.7.1 AGC Biologics Company Detail
11.7.2 AGC Biologics Business Overview
11.7.3 AGC Biologics Mammalian Biopharmaceutical Service Introduction
11.7.4 AGC Biologics Revenue in Mammalian Biopharmaceutical Service Business (2018-2023)
11.7.5 AGC Biologics Recent Development
11.8 Rentschler Biopharma SE
11.8.1 Rentschler Biopharma SE Company Detail
11.8.2 Rentschler Biopharma SE Business Overview
11.8.3 Rentschler Biopharma SE Mammalian Biopharmaceutical Service Introduction
11.8.4 Rentschler Biopharma SE Revenue in Mammalian Biopharmaceutical Service Business (2018-2023)
11.8.5 Rentschler Biopharma SE Recent Development
11.9 Northway Biotech
11.9.1 Northway Biotech Company Detail
11.9.2 Northway Biotech Business Overview
11.9.3 Northway Biotech Mammalian Biopharmaceutical Service Introduction
11.9.4 Northway Biotech Revenue in Mammalian Biopharmaceutical Service Business (2018-2023)
11.9.5 Northway Biotech Recent Development
11.10 Boehringer Ingelheim
11.10.1 Boehringer Ingelheim Company Detail
11.10.2 Boehringer Ingelheim Business Overview
11.10.3 Boehringer Ingelheim Mammalian Biopharmaceutical Service Introduction
11.10.4 Boehringer Ingelheim Revenue in Mammalian Biopharmaceutical Service Business (2018-2023)
11.10.5 Boehringer Ingelheim Recent Development
11.11 AGC
11.11.1 AGC Company Detail
11.11.2 AGC Business Overview
11.11.3 AGC Mammalian Biopharmaceutical Service Introduction
11.11.4 AGC Revenue in Mammalian Biopharmaceutical Service Business (2018-2023)
11.11.5 AGC Recent Development
11.12 Cambrex
11.12.1 Cambrex Company Detail
11.12.2 Cambrex Business Overview
11.12.3 Cambrex Mammalian Biopharmaceutical Service Introduction
11.12.4 Cambrex Revenue in Mammalian Biopharmaceutical Service Business (2018-2023)
11.12.5 Cambrex Recent Development
11.13 Samsung Biologics
11.13.1 Samsung Biologics Company Detail
11.13.2 Samsung Biologics Business Overview
11.13.3 Samsung Biologics Mammalian Biopharmaceutical Service Introduction
11.13.4 Samsung Biologics Revenue in Mammalian Biopharmaceutical Service Business (2018-2023)
11.13.5 Samsung Biologics Recent Development
11.14 FUJIFILM Diosynth Biotechnologies
11.14.1 FUJIFILM Diosynth Biotechnologies Company Detail
11.14.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.14.3 FUJIFILM Diosynth Biotechnologies Mammalian Biopharmaceutical Service Introduction
11.14.4 FUJIFILM Diosynth Biotechnologies Revenue in Mammalian Biopharmaceutical Service Business (2018-2023)
11.14.5 FUJIFILM Diosynth Biotechnologies Recent Development
11.15 GBI
11.15.1 GBI Company Detail
11.15.2 GBI Business Overview
11.15.3 GBI Mammalian Biopharmaceutical Service Introduction
11.15.4 GBI Revenue in Mammalian Biopharmaceutical Service Business (2018-2023)
11.15.5 GBI Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details